Registered Attendees

Registered Attendees

Print This Page

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Close Window
Fairmont Banff Springs Floorplan

Fairmont Banff Springs Floorplan

Print This Page



Close Window
NOTES:
This meeting occurs in 2015.
This meeting will be conducted in English.

All programs are subject to change. Check this site for updates.


Download Flyer

Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)

joint with the meeting on Antibodies as Drugs: Immunological Scaffolds as Therapeutics (J8)

Scientific Organizers: Elizabeth M. Jaffee and Axel Hoos


February 8—13, 2015

Fairmont Banff Springs, Banff, Alberta, Canada


Sponsored by Astellas Pharma Inc., Genmab A/S, Gilead Sciences, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. and TESARO, Inc. Supported by an educational donation provided by Amgen.


Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

DEADLINES:
Scholarship Deadline: Oct 9, 2014 [details]
Discounted Abstract Deadline: Oct 9, 2014 [details]
Abstract Deadline: Nov 12, 2014 [details]
Discounted Registration Deadline: Dec 9, 2014 [details]

Submit an Abstract Register Yourself Deadlines and Fees
Deadlines and Fees for 2015-J7 ''Tumor Immunology: Multidisciplinary Science Driving Combination Therapy''
Print This Page

Rates and Deadlines listed below are for the 2015-J7 "Tumor Immunology: Multidisciplinary Science Driving Combination Therapy" conference only.

*All deadlines end at 11:59 PM US Mountain Standard Time

Deadline Date Cost
Discounted Abstract Deadline
More details
Before and On October 9, 2014 100.00 USD*
- 50.00 USD discount
Abstract Deadline
More details
After October 9, 2014 until November 12, 2014 100.00 USD*
* 50.00 USD of Abstract fee deducted from your registration fee when you register for this meeting
Scholarship
More details
October 9, 2014 n/a
Discounted NON-STUDENT Registration
More details
Before and On December 9, 2014 845.00 USD
(includes 150.00 discount)
Regular NON-STUDENT Registration
More details
After December 9, 2014 995.00 USD
Discounted STUDENT Registration
More details
Before and On December 9, 2014 620.00 USD
(includes 150.00 discount)
Regular STUDENT Registration
More details
After December 9, 2014 770.00 USD

* Changes in payment type that result in a refund are subject to a processing fee.
* Currency exchange gains/losses are the responsibility of the registrant and the Keystone Symposia will    accept no liability for money loss through bank charges, transfers or currency fluctuations.

Close Window



About Discounted Abstract Deadline
About Global Health Travel Award Deadline
About Scholarship Deadline
About Abstract Deadline
About Discounted Registration Deadline

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, FEBRUARY 8

16:00—20:00
Arrival and Registration

18:00—20:00
Mixer


MONDAY, FEBRUARY 9

07:00—08:00
Breakfast

08:00—09:30
Keynote Session
Registered attendees can view abstracts starting on 01/08/2015

Axel Hoos, GlaxoSmithKline, USA
Combination Therapies: Immunology Meets Oncology

Robert D. Schreiber, Washington University School of Medicine, USA
Using Genomics Approaches to Inform Cancer Immunotherapy

08:00—09:00
Keynote Address
Registered attendees can view abstracts starting on 01/08/2015

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
Antibodies Blocking the PD-1 Pathway: A New Age for Cancer Therapy

09:30—11:45
Inflammation and the Dynamics of the Tumor Microenvironment
Registered attendees can view abstracts starting on 01/08/2015

Robert Peter Gale, Hammersmith and Celgene, USA
The Diversity of Myeloid Cell Populations Driving Carcinogenesis

Guido Kroemer, Institut Gustave Roussy, France
The Interconnected Pathways of Genetic and Immunologic Changes in Carcinogenesis

* Elizabeth M. Jaffee, Johns Hopkins University, USA
Combinatorial Immunotherapies with the Potential to Reverse the Carcinogenesis Process

Short Talk(s) Chosen from Abstracts

09:00—11:15
Antibody Drug Conjugates in the Clinic
Registered attendees can view abstracts starting on 01/08/2015

Mark X. Sliwkowski, Genentech, Inc., USA
T-DM1 and Next Generation ADCs in the Clinic: Lessons Learned

Peter D. Senter, Seattle Genetics Inc., USA
Potent Antibody-Based Conjugates for Cancer Therapy: From Early Stage Research to a Clinically Approved Drug

William C. Olson, Regeneron Pharmaceuticals, Inc., USA
Clinical-stage ADCs: What's Trending Amongst this 50ish Crowd

Short Talk(s) Chosen from Abstracts

10:10—10:30
Coffee Break

11:45—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:45—14:30
On Own for Lunch

14:30—16:30
Workshop 1: Integration of Science through Collaboration - New Models

Short Talks Chosen from Abstracts

14:30—16:30
Workshop 1: Novel Scaffolds

Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available

17:00—19:00
Genetics and Epigenetics of the Immune System
Registered attendees can view abstracts starting on 01/08/2015

Tak W. Mak, Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, University Health Network, Canada
Genetic and Epigenetic Alterations that Drive Neoantigen Development

* Laurence Zitvogel, Institut Gustave Roussy, France
Gut Microbiota and Anticancer Immune Responses

Eduardo M. Sotomayor, Moffitt Cancer Center and Research Institute, USA
Combinatorial Approaches that Integrate Epigenetic Therapy with Immunotherapy

Short Talk Chosen from Abstracts

17:00—19:00
Antibody-Targeted Fusion Proteins for Cancer Therapy
Registered attendees can view abstracts starting on 01/08/2015

Christoph Rader†, National Cancer Institute, National Institutes of Health, USA
Talk Title to be Announced

Sherie L. Morrison, UCLA, USA
Antibody Fusions with Interferon for the Treatment of Malignancy

Tibor P. Keler, Celldex Therapeutics, Inc., USA
DC-Targeted Antibody Fusions as Cancer Vaccines

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour with Lite Bites

19:30—22:00
Poster Session 1


TUESDAY, FEBRUARY 10

07:00—08:00
Breakfast

08:00—11:00
Genomic, Metabolomic, and Proteomic Advances in Cancer Immunotherapy
Registered attendees can view abstracts starting on 01/08/2015

* Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
Neo-Antigens in Human Cancer

Speaker to be Announced

Jonathan D. Powell, Johns Hopkins University School of Medicine, USA
mTOR, Metabolism and T Cell Differentiation and Function

Antony Rosen, Johns Hopkins School of Medicine, USA
Cancer and the Autoimmune Rheumatic Diseases: Mechanistic Insights

Short Talk(s) Chosen from Abstracts

08:00—11:00
Antibodies for Cancer Immunotherapy
Registered attendees can view abstracts starting on 01/08/2015

Alan J. Korman, Bristol-Myers Squibb, USA
Antibodies for Immune Checkpoint Blockade

Martin J. Glennie, University of Southampton, Faculty of Medicine, UK
Agonistic Antibodies Targeting Costimulatory Receptors

Pablo Umaña, Roche Innovation Center Zurich, Switzerland
Enhancing Immune Effector Functions of Antibodies: Gazyva and Beyond

Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany
Clinical Progress with T Cell-Engaging Bispecific Antibodies

Short Talk(s) Chosen from Abstracts

09:20—09:40
Coffee Break

11:00—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:00—17:00
On Own for Lunch

16:30—17:00
Coffee Available

17:00—19:00
Human Immunology: Functional Insights for Cancer Immunotherapy
Registered attendees can view abstracts starting on 01/08/2015

* Mark M. Davis, Stanford University, USA
Human Immunology Meets Cancer Immunotherapy

Pia Kvistborg, Netherlands Cancer Institute, Netherlands
Effects of Checkpoint Targeting on the Tumor-Specific T Cell Response

Steven M. Larson, Memorial Sloan-Kettering Cancer Center, USA
Radioimmunotherapy (RIT) of Solid Tumors

Short Talk Chosen from Abstracts

17:00—19:00
Alternative Tumor Targeting Approaches
Registered attendees can view abstracts starting on 01/08/2015

Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Limits of Tumor Targeting in Immunotherapy: Theory and Experiment

Bryan A. Irving, CytomX Therapeutics, Inc, USA
Probodies Empower a New Generation of Antibody Immunotherapies

Bent Jakobsen, Immunocore Ltd., UK
ImmTACs: Bi-specific TCR-based Reagents for Targeted Cancer Immunotherapy

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour with Lite Bites

19:30—22:00
Poster Session 2


WEDNESDAY, FEBRUARY 11

07:00—08:00
Breakfast

08:00—11:00
Influence of Conventional Therapies on the Immune System
Registered attendees can view abstracts starting on 01/08/2015

* Ira Mellman, Genentech, Inc., USA
Targeted Molecular Therapy Takes on Immunotherapy

Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies

Daniel E. Speiser, Ludwig Center, Univ. of Lausanne, Switzerland
Multidisciplinary Approaches to Target both Cancer Cell-Internal and -External Disease Mechanisms

Li Liu, GlaxoSmithKline, USA
Effects of Targeted Therapies on Tumor and Immune System

Short Talk(s) Chosen from Abstracts

08:00—11:00
Clinical Progress with Bispecific Antibodies for Dual Blockade
Registered attendees can view abstracts starting on 01/08/2015

Gabriele Schaefer, Genentech, Inc., USA
Her1/3 DAF for Cancer Therapy

Alexey Lugovskoy, Merrimack Pharmaceuticals Inc., USA
MM-141: Dual Antibody Inhibitor of IGF-1R and ErbB3 Targeting Redundancies and Adaptation in Oncogenic Signaling

Oliver Krieter, Hoffmann-La Roche, Germany
Clinical Progress with RG7221 (RO5520985), a Bi-Specific Human IgG1 Antibody against Ang-2 and VEGF-A for the Treatment of Cancer

Tariq Ghayur, AbbVie, USA
Preclinical and Clinical Progress of Dual-Variable-Domain-Ig (DVD-IgTM) Molecules for Autoimmune Indications

Short Talk(s) Chosen from Abstracts

09:20—09:40
Coffee Break

11:00—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:00—17:00
On Own for Lunch

16:30—17:00
Coffee Available

17:00—19:00
Advances in Therapeutic Platforms: Vaccines, Cellular Therapies and Immune Modulators
Registered attendees can view abstracts starting on 01/08/2015

Laurence J. N. Cooper, University of Texas MD Anderson Cancer Center, USA
Genetic Modification of T Cells using Sleeping Beauty System for Human Applications

* Cornelis J. M. Melief, Leiden University Medical Center, Netherlands
Synergy of Therapeutic Vaccination Against HPV16 Oncogenic Proteins and Conventional Chemotherapeutics

Jolanda de Vries, NCMLS, Netherlands
Natural Dendritic Cell Vaccine: A More Powerful Next Generation?

Short Talk Chosen from Abstracts

17:00—19:00
Antibodies for Infectious Diseases
Registered attendees can view abstracts starting on 01/08/2015

Gerald B. Pier, Harvard Medical School, USA
Anti-Microbial Antibody Therapy

Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Broadly Neutralizing Anti-Viral Antibodies

David D. Ho†, Rockefeller University, USA
Engineering Bispecific Anti-HIV Antibodies

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour with Lite Bites

19:30—22:00
Poster Session 3


THURSDAY, FEBRUARY 12

07:00—08:00
Breakfast

08:00—11:00
Methodological Advances in Clinical and Biomarker Investigation
Registered attendees can view abstracts starting on 01/08/2015

Ugur Sahin†, TRON – Translationale Oncology, Germany
Advances in Measuring Immune Function in the Tumor and the Blood

James P. Allison, HHMI/University of Texas MD Anderson Cancer Center, USA
Investigating Emerging Checkpoint Targets and their Modulators

* Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center, USA
Combination Checkpoint Blockade

A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, USA
Inflammation Biomarkers and Vaccines

Short Talk(s) Chosen from Abstracts

08:00—11:00
Engineering Immunological Scaffolds for Improved Delivery and Disposition
Registered attendees can view abstracts starting on 01/08/2015

Serge Muyldermans, Vrije Universiteit Brussel, Belgium
Nanobodies for Alternative Delivery Routes

Kristen M. Picha, Centyrex, Janssen Research & Development, USA
Novel Delivery Strategies for Alternative Scaffolds

Tomoyuki Igawa, Chugai Pharmaceutical, Japan
Engineered pH Dependent Binding Antibody for Efficient Elimination of soluble Antigen from Plasma

Michael Stumpp, Molecular Partners, Switzerland
DARPins for Ocular Diseases and Beyond

Short Talk(s) Chosen from Abstracts

09:20—09:40
Coffee Break

11:00—14:30
On Own for Lunch

14:30—16:30
Workshop 2: Re-Visiting Past Approaches to Cancer Immunotherapy - Lessons from Failures to Enable Future Successes

Short Talks Chosen from Abstracts

14:30—16:30
Workshop 2: New Library Design and Screening Technologies

Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available

17:00—18:45
Scientific and Clinical Progress in Combination Therapy
Registered attendees can view abstracts starting on 01/08/2015

* Axel Hoos, GlaxoSmithKline, USA

F. Stephen Hodi, Dana Farber Cancer Institute, USA
Recent Progress of Clinical Combinations with Immune Checkpoint Inhibitors

Harpreet Singh, immatics Biotechnologies, Germany
Combinations of Cancer Vaccines and Other Modalities

Silvia C. Formenti, NYU Langone Medical Center, USA
Combination Therapy Potential of Radiation Therapy as in-situ Vaccination

17:00—18:45
Addressing Difficult Targets - GPCRs and Ion Channels
Registered attendees can view abstracts starting on 01/08/2015

Catherine Hutchings, Heptares Therapeutics, UK
Using Stabilised Receptors as Antigens to Generate Therapeutic Antibodies to GPCR Targets

Vaughn V. Smider, The Scripps Research Institute, USA
Ultralong CDR3s for Targeting Ion Channels and GPCRs

Caroline Colley, MedImmune, UK
Identifying Antibodies to GPCRs and Ion-Channels

18:45—19:15
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 01/08/2015

18:45—19:15
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 01/08/2015

19:15—20:15
Social Hour with Lite Bites

20:00—23:00
Entertainment


FRIDAY, FEBRUARY 13

 
Departure


*Session Chair †Speaker invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Educational donation provided by Amgen Astellas Pharma Inc.
Genmab A/S Gilead Sciences, Inc.
Incyte Corporation Infinity Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. TESARO, Inc.

We gratefully acknowledge additional support for this conference from:

Cell Signaling Technology, Inc.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



AbbVie Inc.


Amgen Inc.


BioNTech RNA Pharmaceuticals GmbH


Immatics Biotechnologies GmbH


Janssen R&D: Pharmaceutical Companies of Johnson & Johnson


MedImmune


Regeneron Pharmaceuticals, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Amanda Deem, Assistant Director of Development, Email: AmandaD@keystonesymposia.org,
Phone:+1 970-262-2668

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676